Literature DB >> 7014468

Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody.

T R Kozel, J L Follette.   

Abstract

Antisera prepared in rabbits against either whole encapsulated cells of Cryptococcus neoformans or purified cryptococcal polysaccharide were opsonic for the encapsulated yeast. The opsonic activity was removed by absorption with whole cryptococci and was inhibited by free polysaccharide. As little as 0.13 microgram of cryptococcal polysaccharide produced a 50% inhibition of opsonization. Various degrees of neutralization by polysaccharides from the four cryptococcal serotypes suggested that the opsonins were type specific. Fractionation of antiserum on Bio-Gel A-5m (Bio-Rad Laboratories) and diethylaminoethyl cellulose showed that the opsonins were antibodies of the immunoglobulin G class. These opsonizing antibodies did not require heat-labile serum components for optimal phagocytosis of the yeast. Inhibition studies using 2-deoxy-D-glucose demonstrated that ingestion of encapsulated cryptococci opsonized with anticapsular antibody was a 2-deoxy-D-glucose-inhibitable process. This result differed from similar studies with non-encapsulated cryptococci which showed that ingestion of non-encapsulated cryptococci opsonized with normal serum was not inhibited by 2-deoxy-D-glucose.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7014468      PMCID: PMC351414          DOI: 10.1128/iai.31.3.978-984.1981

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  CRYPTOCOCCUS NEOFORMANS POLYSACCHARIDE: STUDIES OF SEROLOGIC PROPERTIES AND ROLE IN INFECTION.

Authors:  J E BENNETT; H F HASENCLEVER
Journal:  J Immunol       Date:  1965-06       Impact factor: 5.422

2.  Effects of stimulation and suppression of cell-mediated immunity on experimental cryptococcosis.

Authors:  R D Diamond
Journal:  Infect Immun       Date:  1977-07       Impact factor: 3.441

3.  The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection.

Authors:  R D Diamond; J E May; M A Kane; M M Frank; J E Bennett
Journal:  J Immunol       Date:  1974-06       Impact factor: 5.422

4.  Factors influencing killing of Cryptococcus neoformans by human leukocytes in vitro.

Authors:  R D Diamond; R K Root; J E Bennett
Journal:  J Infect Dis       Date:  1972-04       Impact factor: 5.226

5.  Serology of human cryptococcosis.

Authors:  D D Bindschadler; J E Bennett
Journal:  Ann Intern Med       Date:  1968-07       Impact factor: 25.391

6.  Experimental murine cryptococcosis: effect of hyperimmunization to capsular polysaccharide.

Authors:  M B Goren
Journal:  J Immunol       Date:  1967-05       Impact factor: 5.422

7.  Formation of histiocyte rings in response to Cryptococcus neoformans infection.

Authors:  S Schneerson-Porat; A Shahar; M Aronson
Journal:  J Reticuloendothel Soc       Date:  1965-09

8.  Phagocytosis of Cryptococcus neoformans by normal and thioglycolate-activated macrophages.

Authors:  F J Swenson; T R Kozel
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

9.  Opsonization of Cryptococcus neoformans by human immunoglobulin G: role of immunoglobulin G in phagocytosis by macrophages.

Authors:  T R Kozel; T G McGaw
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

10.  Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide.

Authors:  T R Kozel; J Cazin
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

View more
  31 in total

1.  Opsonic requirements for dendritic cell-mediated responses to Cryptococcus neoformans.

Authors:  Ryan M Kelly; Jianmin Chen; Lauren E Yauch; Stuart M Levitz
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

Review 2.  Antibody immunity and invasive fungal infections.

Authors:  A Casadevall
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

Review 3.  Cryptococcal interactions with the host immune system.

Authors:  Kerstin Voelz; Robin C May
Journal:  Eukaryot Cell       Date:  2010-04-09

4.  Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.

Authors:  Raymond M Duro; Dale Netski; Peter Thorkildson; Thomas R Kozel
Journal:  Clin Diagn Lab Immunol       Date:  2003-03

5.  Genetic control of the humoral response to cryptococcal capsular polysaccharide in mice.

Authors:  F Dromer; P Yeni; J Charreire
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

Review 6.  Immunity in cryptococcosis: an overview.

Authors:  R A Fromtling; H J Shadomy
Journal:  Mycopathologia       Date:  1982-03-19       Impact factor: 2.574

7.  Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.

Authors:  J Mukherjee; L S Zuckier; M D Scharff; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

Review 8.  An overview of macrophage-fungal interactions.

Authors:  R A Fromtling; H J Shadomy
Journal:  Mycopathologia       Date:  1986-02       Impact factor: 2.574

9.  Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses.

Authors:  H L Collins; G J Bancroft
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

10.  Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans.

Authors:  S L Zebedee; R K Koduri; J Mukherjee; S Mukherjee; S Lee; D F Sauer; M D Scharff; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.